

CORRECTION

Open Access



Correction to: Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study

Ting Yang^{1,2}, Baiqiang Cai³, Bin Cao^{1,2}, Jian Kang⁴, Fuqiang Wen⁵, Yahong Chen⁶, Wenhua Jian⁷, Hongyan Shang⁸ and Chen Wang^{1,2*} 

Correction to: *Respiratory Research* (2022) 23:106

<https://doi.org/10.1186/s12931-022-02021-w>

Following the publication of the original article [1], the authors identified errors in the study enrolment dates in the Abstract and Results sections. The dates “15 December 2017 and 6 August 2020” should be corrected to “30 June 2017 and 29 January 2019”.

The original article has been corrected.

Reference

1. Yang T, Cai B, Cao B, Kang J, Wen F, Chen Y, Jian W, Shang H, Wang C. Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study. *Respir Res.* 2022;23:106. <https://doi.org/10.1186/s12931-022-02021-w>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China. ²National Clinical Research Center for Respiratory Diseases, Beijing 100029, China. ³Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China. ⁴Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, China. ⁵Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. ⁶Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China. ⁷State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ⁸Department of Medical Affairs, AstraZeneca China, Shanghai, China.

Published online: 18 June 2022

The original article can be found online at <https://doi.org/10.1186/s12931-022-02021-w>.

*Correspondence: wangchen66366@163.com

¹ Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.